These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 22743574)

  • 1. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
    Cremeans CM; Gruley E; Kyle DJ; Ko MC
    J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
    Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
    Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
    J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.
    Flynn SM; Epperly PM; Davenport AT; Cami-Kobeci G; Husbands SM; Ko MC; Czoty PW
    Neuropsychopharmacology; 2019 Jul; 44(8):1476-1484. PubMed ID: 30970376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.
    Ko MC; Woods JH; Fantegrossi WE; Galuska CM; Wichmann J; Prinssen EP
    Neuropsychopharmacology; 2009 Aug; 34(9):2088-96. PubMed ID: 19279568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).
    Varty GB; Lu SX; Morgan CA; Cohen-Williams ME; Hodgson RA; Smith-Torhan A; Zhang H; Fawzi AB; Graziano MP; Ho GD; Matasi J; Tulshian D; Coffin VL; Carey GJ
    J Pharmacol Exp Ther; 2008 Aug; 326(2):672-82. PubMed ID: 18492950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Profile of Systemic and Intrathecal Cebranopadol in Nonhuman Primates.
    Ding H; Trapella C; Kiguchi N; Hsu FC; Caló G; Ko MC
    Anesthesiology; 2021 Sep; 135(3):482-493. PubMed ID: 34237134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
    Lin AP; Ko MC
    ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.
    Saccone PA; Zelenock KA; Lindsey AM; Sulima A; Rice KC; Prinssen EP; Wichmann J; Woods JH
    J Pharmacol Exp Ther; 2016 Apr; 357(1):17-23. PubMed ID: 26801398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.
    Kallupi M; Shen Q; de Guglielmo G; Yasuda D; Journigan VB; Zaveri NT; Ciccocioppo R
    Addict Biol; 2018 Mar; 23(2):585-595. PubMed ID: 28635181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
    Cornelissen JC; Steele FF; Tenney RD; Obeng S; Rice KC; Zhang Y; Banks ML
    Eur J Pharmacol; 2019 Feb; 844():175-182. PubMed ID: 30552903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue.
    Recker MD; Higgins GA
    J Pharmacol Exp Ther; 2004 Nov; 311(2):652-8. PubMed ID: 15226383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices.
    Chiou LC; Chuang KC; Wichmann J; Adam G
    J Pharmacol Exp Ther; 2004 Nov; 311(2):645-51. PubMed ID: 15254141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.
    Ko MC; Naughton NN
    J Pain; 2009 May; 10(5):509-16. PubMed ID: 19231294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies.
    Ko MC; Wei H; Woods JH; Kennedy RT
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1257-64. PubMed ID: 16766718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
    Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
    J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
    Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
    Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central N/OFQ-NOP Receptor System in Pain Modulation.
    Kiguchi N; Ding H; Ko MC
    Adv Pharmacol; 2016; 75():217-43. PubMed ID: 26920014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
    Kiguchi N; Ding H; Ko MC
    J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.